Alnylam Pharmaceuticals (NASDAQ:ALNY) Given “Outperform” Rating at William Blair

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a report released on Tuesday,RTT News reports.

Several other research firms have also commented on ALNY. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Finally, Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $248.79 on Tuesday. The company has a fifty day simple moving average of $273.83 and a two-hundred day simple moving average of $236.76. The company has a market cap of $32.09 billion, a price-to-earnings ratio of -94.96 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the previous year, the business posted $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. As a group, equities analysts anticipate that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Souders Financial Advisors boosted its holdings in Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 36 shares during the period. Huntington National Bank raised its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares in the last quarter. SYM FINANCIAL Corp raised its stake in shares of Alnylam Pharmaceuticals by 6.2% in the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 55 shares in the last quarter. Lindbrook Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 11.1% in the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 57 shares in the last quarter. Finally, V Square Quantitative Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 60 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.